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Abstract
Background Few clinical studies or randomized clinical
trial results have reported the impact of fast-track surgery
on human immunity. This study aimed to investigate the
clinical and immune impact of fast-track surgery in colo-
rectal cancer patients undergoing elective open surgery.
Methods A controlled randomized clinical trial was
conducted from November 2008 to January 2009 with a
1-month postdischarge follow-up. A total of 70 patients
with colorectal carcinoma requiring colorectal resection
were randomized into two groups: a fast-track group (35
cases) and a conventional care group (35 cases). All
included patients underwent elective open colorectal
resection with combined tracheal intubation and general
anesthesia. Clinical parameters and markers of immune
function were evaluated in both groups postoperatively.
Results In all, 62 patients completed the study: 32 in the
fast-track group and 30 in the conventional care group. Our
findings revealed a significantly shorter postoperative
hospital stay and faster return of gastrointestinal function in
patients undergoing fast-track rehabilitation. In addition,
we found a quicker response of white blood cells in the
fast-track group than in the conventional care group. We
also found that blood levels of globulin, immunoglobulin
G, and complement 4 on postoperative day 3 were higher
in the fast-track group than in the conventional care group.
Conclusions Fast-track surgery accelerates clinical
recovery and improves postoperative immunity after elec-
tive open surgery for colorectal carcinoma.
Introduction
Fast-track surgery (FTS) is a promising comprehensive
program for surgical patients. It aims to decrease the per-
ioperative stress response to the surgical trauma, thereby
leading to a decrease in complication rates after elective
surgery [1, 2]. Numerous clinical trials have provided
positive evidence of the benefits of utilizing FTS, including
improving postoperative recovery, shortening the hospital
stay, accelerating the return of gastrointestinal function,
and reducing morbidity and mortality rates [3–6]. Some
researchers believe that FTS also has positive effects on the
human immune system, which may result in quicker
recovery of postoperative immune function [7]. Neverthe-
less, few clinical studies or randomized clinical trial (RCT)
results have reported the impact of FTS on human immu-
nity. Therefore, based on the hypothesis and present evi-
dence of the benefits of FTS, this prospective, randomized
comparative study investigated the effects of FTS on
postoperative clinical recovery and immunity in patients
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Sun Yat-sen University from November 2008 to January
2009. The surgical procedures were performed by experi-
enced surgeons (they had performed at least 200 colorectal
procedures before participating in the study). Seventy
patients who were clinically diagnosed as having colorectal
carcinoma were assigned randomly to two groups com-
prising 35 patients each: FTS group and conventional care
group. Inclusion criteria included: age C18 and B80 years,
no preoperative chemotherapy or radiotherapy, American
Society of Anesthesiologists (ASA) grade I/II, body mass
index (BMI) 17.5–27.5 kg/m2, preoperative serum albumin
C30 g/l. All of the patients underwent elective open
colorectal resection with combined tracheal intubation and
general anesthesia. Exclusion criteria included immune-
related disease; primary diabetes mellitus or impaired
glucose tolerance; hiatus hernia; gastroesophageal reflux
disease (GERD); pregnancy; bowel obstruction; patients
with difficult airway access (difficult to intubate); and drug
intake, which might affect bowel movement and function.
Patients also would be excluded if the following circum-
stances occurred: failure of thoracic epidural catheter
insertion; intraoperative blood transfusion; patients who
required a stoma; unresectable carcinoma.
The study protocol was approved by the Research Ethics
Committee of the First Affiliated Hospital of Sun Yat-sen
University (Guangzhou, China). Written informed consents
were obtained from the patients and their families. This
study was registered under chictr.org, identifier number
ChiCTR-TRC-00000157.
Interventions
The intervention protocols of the FTS group were as follows:
normal meal until 10 p.m. the day before surgery; drink
250 ml of 5 % carbohydrate 2 h before surgery [8]; no
routine nasogastric tube drainage; early as possible removal
of urine and venous catheters (urinary catheter: removed
when the patient became conscious and could be mobilized
out of bed; deep venous catheter: removed when vital signs
were stable); oral feeding started 6–12 h after surgery, fol-
lowing a stepwise plan from oral liquid nutrition to normal
diet. Ensure (400 g; Abbott, Chicago, IL, USA) was applied
as oral nutrition and was mixed with water for 1 Kcal/ml.
The oral feeding plan was as follows: 6–12 h after surgery,
Ensure mixture, 30–50 ml every 1–2 h; postoperative day
(POD) 2 and afterward, Ensure mixture, 100–200 ml every
2–3 h, plus semi-fluids according to the patient’s tolerance.
Mobilization was encouraged from the night of the opera-
tion. Patients were encouraged to meet predefined mobility
targets over the postoperative days.
The intervention protocols of the conventional group
were as follows: normal meal until 10 p.m. the day before
surgery, routine use of nasogastric tube drainage, and oral
intake initiated on return to normal gastrointestinal func-
tion (bowel sounds or flatus) following a stepwise plan
from oral liquid nutrition (Ensure 400 g) to a normal diet.
Patients were sat up and assisted to mobilize on POD 1, but
they were not aggressively mobilized until discontinuation
of the thoracic epidural. Urinary catheters were removed
following epidural catheter removal.
The same interventions were applied in both groups:
Routine bowel preparation was done with gentamicin and
metronidazole. Polyethylene glycol electrolyte powder
(HYGECON, Jiangxi, China) was used as a laxative. Other
measures included prophylactic use of antibiotics; avoid-
ance of long-acting opioids; intraoperative maintenance of
normothermia with an upper-body forced-air heating
cover; a midline incision of minimal length; intraoperative
and postoperative fluid restriction; no routine use of
abdominal drains; the combination of continuous epidural
mid-thoracic local anesthetics plus nonsteroidal antiin-
flammatory drugs (NSAIDs) to control postoperative pain.
Postoperative blood glucose was controlled with the fasting
blood glucose (FBG) level maintained at \12 mmol/l.
Administration of any blood product was unacceptable, as
was giving any agent that could affect immunity. Total
postoperative calorie administration was controlled in the
range of 25–30 Kcal/kg per 24 h in both groups.
Discharge criteria included the following: normal body
temperature; independently mobile; return to normal gas-
trointestinal function (defecation at least once); normal oral
diet, no need for parenteral nutrition; controllable pain with
oral analgesia; willing to go home. Patients were read-
mitted at the request of the primary care physician or if the
patient made direct contact with the hospital describing
deteriorating health at home. Patients were followed up
within 1 month after discharge (follow-up by telephone
every 3 days during the first 2 weeks, once a week during
the last 2 weeks). The patient was told that the researcher
should be informed promptly if the patient had any
discomfort.
Both groups were protocol-driven, with checklists for
patients, nursing staff, and surgical staff to help maintain
compliance. Teaching sessions and dummy runs were held
before trial commencement to clarify potential points of
confusion and reduce protocol violations. Patients were
admitted to one of two nursing areas depending on the
results of randomization. Although the interventions were
protocol-driven, a geographically separate location was
considered desirable to minimize protocol contamination.
Measurements
Patients’ preoperative self-feelings were evaluated before
anesthesia induction (e.g., thirsty, hungry). Anesthe-
sia-related complications were measured. Intraoperative
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measurements were carefully recorded in detail, including
surgical procedures, blood loss, fluid transfusion, and blood
transfusion, among others. The return of normal gastroin-
testinal function (time to first bowel sounds/flatus, defeca-
tion, initiation of soft diet), hospital stay, and complications
were recorded postoperatively. Blood tests [white blood cell
(WBC) count, liver function tests (LFTs), serum biochem-
istry, humoral immunologic index] were performed on
appointed days. The humoral immunologic factors tested in
our study included serum globulin, immunoglobulin G
(IgG), immunoglobulin M (IgM), immunoglobulin A (IgA),
complement 3 (C3), and complement 4 (C4).
Experimental blood tests were performed on the morn-
ing of the operation and on PODs 1, 3, and 7. All blood
samples were taken from peripheral veins at 6 a.m., before
breakfast. We also took blood samples to test the WBC
count at the end of surgery.
Sample size, randomization, and implementation
The intention of our study was to detect possible changes
of human immunity on the basis of clinical benefits. Like
many other clinical studies, we selected the length of
hospital stay (LOS) as the main endpoint. On the basis of
previous data for postoperative LOS, (10.38 days on
average) for patients undergoing major colonic surgery at
our institution, we calculated that 35 patients in each group
would be required to detect a 30 % reduction in postop-
erative LOS with an a level of 0.05 and a b level of 0.01.
Patients were informed about the aims and details of this
study. Patients signed consent forms after the study was
explained. Block randomization was computer-generated.
Eligible patients were randomly assigned in a 1:1 ratio. The
investigators who designed the study prepared the enve-
lopes and assigned participants to their groups but had no
contact with the patients throughout the study. The inves-
tigator recruiting the patients, administering the interven-
tions, and evaluating the outcomes had no role in the
randomization process.
Statistical analyses
Data were analyzed using SPSS for Windows 13.0 (SPSS,
Chicago, IL, USA). Numerical variables were expressed as
the mean ± SD unless otherwise stated. Categoric vari-
ables were expressed by a constituent ratio or rate. Dif-
ferences between the two groups were tested using a two-
tailed Student’s t test for normally distributed data and the
Wilcoxon test for noncontinuous variables. The v2 test and
Fisher’s exact test were used to compare discrete variables.
A value of p \ 0.05 was considered statistically significant.
Compared with our primary protocol, we made a mod-
ification to the enrollment of participants before trial
commencement, which initially intended to enroll patients
with gastrointestinal tumors other than colorectal cancer.
The aim was to control the homogeneity of the patients and
thus control bias. The sample size decreased from 60 to 35
accordingly. The Research Ethics Committee of the First
Affiliated Hospital of Sun Yat-sen University (Guangzhou,
China) approved all the changes.
Results
In all, 62 patients finished the study, including 32 patients
in the FTS group and 30 in the conventional care group.
Three patients were excluded from the FTS group and five
patients from the conventional care group. (Fig. 1) Patients
in the two groups had comparable preoperative baseline
characteristics, including sex, age, serum hemoglobin and
albumin levels, and body mass index (Table 1).
No statistically significant differences were detected
between the two groups regarding the operating time, blood
loss or fluid transfusion during the operation, surgical
procedure, or tumor staging. However, patients in the FTS
group did experience significantly less discomfort in terms
of hunger and thirst (Table 1).
Postoperative clinical parameters
Patients in the FTS group showed significantly accelerated
recovery of gastrointestinal function compared to that of
the conventional care group in terms of time to first bowel
sounds/flatus (2 ± 1 vs. 4 ± 2 days, p \ 0.05), defecation
(3.84 ± 1.63 vs. 6.44 ± 2.53 days, p \ 0.05), and initia-
tion of soft diet (4.0 ± 2.0 vs. 8.2 ± 2.16 days, p \ 0.05).
Postoperative hospital stay was significantly shorter in the
FTS group than in the conventional care group (6.0 ± 1.0
vs. 11.7 ± 3.82 days, p \ 0.05).
Although no statistically significant differences were
found for the surgical site infection (SSI) rate (2/30 vs.
1/32, p = 0.6066), pneumonia (1/30 vs. 0/32, p = 0.4839),
and intestinal dysbiosis (5/30 vs. 1/32, p = 0.0986)
between conventional care and FTS groups, patients in the
FTS group had a significantly lower rate of total infectious
complications than did the conventional group (8/30 vs.
2/32, p \ 0.05). No statistically significant differences
were found for noninfectious complications between the
conventional care and FTS groups (4/30 vs. 4/32, p =
1.0000), including vomiting (1/30 vs. 3/32, p = 0.6132),
stress ulcer (1/30 vs. 0/32, p = 0.4839), arrhythmia (1/30
vs. 0/32, p = 0.4839), and urine distension (1/30 vs. 1/32,
p = 1.0000). No anastomotic leakage, anastomotic bleed-
ing, abdominal infection, anesthesia-related complications,
or hospital readmissions due to complications were detec-
ted in either group.
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White blood cell count
A statistically significant difference was found regarding
the WBC count at the end of surgery, with a higher WBC
count found in the FTS group than in the conventional care
group (Table 2). No statistically significant difference was
detected in levels of WBC count on the morning of the day
of the operation. The tendencies for WBC count change
were different in the two groups. In the FTS group, the
WBC count rose quickly to the highest point at the end of
surgery and then dropped gradually to a normal level on
POD 7. In conventional group, the WBC count quickly
rose to a high level at the end of surgery and fluctuated at
that high level until POD 7 (Table 2). Thus, the FTS group
had a quicker WBC response, including rising and drop-
ping counts, than the conventional care group.
Humoral immunologic parameters
No statistically significant differences were detected in
preoperative levels of serum globulin, IgG, IgM, IgA, C3,
or C4 between the two groups. On POD 3, statistically
significant differences were found in levels of serum
globulin, IgG, and C4, with the FTS group having higher
levels than in the conventional group (Table 3).
No statistically significant differences were detected in
the postoperative levels of serum IgM, IgA, or C3 between
the two groups (Table 3). There were also no statistically
significant differences in the recovery rates of all factors
(Table 4).
Discussion
Numerous clinical trials have provided positive evidence of
the benefits of utilizing FTS [3–6]. However, most of the
FTS studies or reviews/meta-analysis intended only to
determine the clinical impact of FTS [3–6, 9–12], with only
a few studies evaluating the impact of FTS on human
immunity. The aim of the present RCT was to evaluate
prospectively the clinical and immunologic results of fast-
track colorectal surgery.
Interpretation
In this study, the principal differences between the two arms
concern a shorter period of preoperative starvation, early
removal of catheters, early oral feeding, and earlier mobili-
zation. Our findings indicate that FTS leads to a significantly
faster recovery of gastrointestinal function, as indicated by
time to first flatus, bowel movements, and initiation of a soft
diet. In addition, patients in the FTS group suffered signifi-
cantly fewer infectious complications without increasing
noninfectious ones. In agreement with these clinical advan-
tages, we observed a significant decrease in the postoperative
length of hospital stay in fast-track patients.
As far as the immunologic effects are concerned, one
study demonstrated that, compared to carbohydrate intake
before surgery, fasting may abate the expression of
monocyte HLA-DR postoperatively [13]. Another study
showed that the use of FTS perioperatively enhanced the
human body’s cellular immunologic ability [i.e., T cells,
Th cells, natural killer (NK) cells] [7]. In this clinical trial,
Fig. 1 Patient flow throughout
the study. FTS fast-track surgery
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we found that the FTS group had a higher WBC count than
did the conventional care group at the end of surgery. In
addition, the FTS group had a quicker WBC response,
including rising and dropping counts, than the conventional
care group. Although we did not test the differences in the
WBC subgroups, the changes that were seen represented
some degree of cell-mediated immunity difference between
the two groups.
Until now, no studies have reported the effect of FTS on
human humoral immunity. Our results indicated that FTS
accelerated the recovery of serum globulin. As we know,
immunoglobulin and complement are two vital elements of
globulin [14, 15]. Our findings showed that FTS group had
significantly higher levels of serum IgG and C4 on POD 3.
With its high affinity and wide distribution, IgG is the most
abundant immunoglobulin in the blood and extracellular
fluid, playing a major role in the immune response to fight
Table 1 Patients’ preoperative/intraoperative characteristics
Characteristic FTS Conventional
(n = 32) (n = 30)
Age (years) 57.2 ± 11.70 59.5 ± 12.10
Sex (no.)
Male 20 (62.5 %) 22 (73.3 %)
Female 12 (37.5 %) 8 (26.7 %)
Body mass index (kg/m2) 22.25 ± 2.45 21.69 ± 2.48
Hemoglobin (g/l) 125.8 ± 18.8 129.8 ± 20.1
Albumin (g/l) 40.84 ± 2.95 40.67 ± 3.58
Preoperative feeling (no.)
Thirsty* 2 (6.3 %) 23 (76.7 %)
Hungry* 5 (15.6 %) 20 (66.7 %)
Operating time (min) 209 ± 40.1 196 ± 50.6
Blood loss (ml) 150 ± 100a 200 ± 100a
Fluid transfusion (ml) 2800 ± 500a 2925 ± 500a
Type of surgery (no.)
Right hemicolectomy 6 (18.7 %) 7 (23.3 %)
Left hemicolectomy 2 (6.3 %) 3 (10.0 %)
Sigmoidectomy 6 (18.7 %) 7 (23.3 %)
Dixon operation 18 (56.3 %) 13 (43.3 %)
Tumor staging (no.)
TNM classification
I 5 (15.6 %) 7 (23.3 %)
II 18 (56.3 %) 16 (53.3 %)
III 9 (28.1 %) 7 (23.3 %)
Dukes classification
A 5 (15.6 %) 7 (23.3 %)
B 18 (56.3 %) 16 (53.3 %)
C1 3 (9.4 %) 2 (6.7 %)
C2 6 (18.7 %) 5 (16.7 %)
FTS fast-track surgery
Variables were expressed as the median ± quartile
a Not subject to normal distribution
* p \ 0.05
Table 2 White blood cell count
Time FTS Conventional Statistic p
(n = 32) (n = 30) (Z)
Before surgery 6.94 ± 2.08 6.21 ± 2.35a -1.5264 0.1269
End of surgery 12.38 ± 3.16 10.65 ± 2.58a -2.1785 0.0294
POD 1 11.84 ± 2.57 10.15 ± 2.57a -1.3838 0.1664
POD 3 10.45 ± 5.28a 11.08 ± 2.23 0.2831 0.7771
POD 7 8.55 ± 5.70a 10.25 ± 5.52a 1.3172 0.1878
POD postoperative day
Variables were expressed as the median ± quartile
a Not subject to normal distribution
Table 3 Serum level of humoral immunologic factors
Factor
and time
FTS Conventional Statistic p
(n = 32) (n = 30)
Globulin (g/l)
Before surgery 27.6 ± 4.0 26.4 ± 4.9 T = 0.9174 0.3643
POD 1 21.6 ± 3.4 19.6 ± 3.5 T = 1.8923 0.0657
POD 3 24.1 ± 2.4 22.1 ± 3.3 T = 2.3257 0.0252
POD 7 27.5 ± 3.7 26.6 ± 4.5 T = 0.721 0.4753
IgG (g/l)
Before surgery 13.76 ± 3.35 11.81 ± 2.66 T = 1.98 0.0559
POD 1 10.35 ± 2.61 8.99 ± 2.32 T = 1.6496 0.1080
POD 3 10.79 ± 2.39 8.66 ± 2.09 T = 2.8828 0.0067
POD 7 13.27 ± 2.82 11.29 ± 3.09 T = 2.0102 0.0524
IgA (g/l)
Before surgery 2.51 ± 1.08a 2.44 ± 1.07a Z = –0.3381 0.7353
POD 1 2.03 ± 0.65 1.88 ± 0.59 T = 0.7213 0.4754
POD 3 2.33 ± 0.66 2.07 ± 1.00a Z = -1.0525 0.2926
POD 7 2.98 ± 0.96 2.94 ± 1.07 T = 0.1393 0.8900
IgM (g/l)
Before surgery 1.01 ± 0.38 1.04 ± 0.41 T = -0.2270 0.8217
POD 1 0.71 ± 0.29 0.78 ± 0.27 T = -0.6878 0.496
POD 3 0.78 ± 0.36 0.75 ± 0.31 T = 0.2685 0.7898
POD 7 1.09 ± 0.59a 1.52 ± 0.85 Z = 0.9727 0.3307
C3 (g/l)
Before surgery 1.08 ± 0.17 0.99 ± 0.20 T = 1.5005 0.142
POD 1 0.82 ± 0.14 0.76 ± 0.17 T = 1.2622 0.215
POD 3 0.82 ± 0.15 0.73 ± 0.20 T = 1.5935 0.1198
POD 7 0.99 ± 0.23 0.88 ± 0.26 T = 1.4533 0.1551
C4 (g/l)
Before surgery 0.29 ± 0.10 0.26 ± 0.07 T = 1.23 0.2274
POD 1 0.21 ± 0.08 0.19 ± 0.06a Z = -1.0749 0.2824
POD 3 0.24 ± 0.09 0.17 ± 0.05a Z = -2.1099 0.0349
POD 7 0.28 ± 0.12 0.22 ± 0.10a Z = -1.7498 0.0801
Ig immunoglobulin, C3, C4 complement 3 and 4, respectively
Variables were expressed as the median ± quartile
a Not subject to normal distribution
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infectious pathogens [14]. The complement system is an
important component of the innate immune system. The
major functions of the complement system include direct
killing of microorganisms; opsonization of microorganisms
for phagocytosis, chemotaxis, and activation of leukocytes
and mast cells; and processing of immune complexes and
regulation of antibody production by B cells. C4 plays a key
role in the classic and lectin pathways, which are the two
major pathways to activate the complement system. Com-
plement also plays an important role in adaptive immunity
involving T and B cells, which help in the elimination of
pathogens [14–16].
The correlation of clinical findings with the immune
parameters indicates that the beneficial clinical data
reported here are associated with better-preserved immu-
nity. However, the mechanisms need to be further studied.
Generalizability and limitations of the study
We found the fact that FTS has a positive impact on
WBCs, but it is unfortunate that we did not test the changes
in the WBC subgroups. Our results did not detect statisti-
cally significant changes in serum IgA, IgM, or C3 between
the two groups. However, this does not mean that FTS has
no effects on these factors, which may be explained by the
time that blood samples were taken or the relatively small
number of cases in our trial. Also, we did not intend to
identify the precise mechanism by which FTS affects the
immunity.
Patients recruited in our study were relatively healthy
and underwent elective open colorectal resection. The
conclusions of this study may not be able to be extrapolated
to patients who do not meet the same inclusion criteria.
Conclusions
Our study suggests that fast-track surgery accelerates
clinical recovery and improves postoperative immunity in
patients undergoing elective open surgery for colorectal
carcinoma. The precise mechanism of how FTS affects the
immunity needs further study.
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